Related Experiment Video
Updated: Jun 22, 2026
10:01
Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain
Published on: October 25, 2017
Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries
Michael Baine1, Daniel S Georgie, Elelta Z Shiferraw
1Department of Chemistry and Biochemistry, Loyola Marymount University, One LMU Drive, Los Angeles, CA 90045, USA.
Summary
Researchers identified peptides that inhibit amyloid-beta 42 (Abeta42) aggregation, a key factor in Alzheimer's disease. One peptide also demonstrated the ability to break down existing Abeta42 fibers, offering potential therapeutic strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Drug Discovery
Background:
- Alzheimer's disease (AD) is linked to the aggregation of amyloid-beta 42 (Abeta42) peptides.
- Inhibiting Abeta42 aggregation is a potential therapeutic strategy for AD.
Purpose of the Study:
- To identify peptides that inhibit Abeta42 aggregation using an in vivo screening method.
- To characterize the inhibitory and disaggregating capabilities of identified peptides.
Main Methods:
- An in vivo screen utilizing the enzyme enhanced green fluorescent protein (EGFP) was employed.
- Two diverse peptide libraries were screened for inhibitors of Abeta42 aggregation.
- Thioflavin T (ThT) assays were used to assess amyloid aggregation inhibition and disaggregation.
Main Results:
- Three candidate peptides were identified from the screening.
- All three selected peptides demonstrated the ability to inhibit Abeta42 amyloid aggregation.
- One peptide showed efficacy in disaggregating pre-formed Abeta42 fibers.
Conclusions:
- The identified peptides show promise in preventing or slowing Alzheimer's disease progression by inhibiting Abeta42 aggregation.
- One peptide's disaggregating activity offers a novel therapeutic avenue for established Abeta42 pathology.
